Note 11 - Segment Information (Tables)

12 Months Ended

Jun. 30, 2017

	Year Ended June 30,
	2017			2016			2015
External sales
Biotechnology	$	364,504		$	317,340		$	308,437
Protein Platforms		91,464			77,324			66,249
Diagnostics		107,139			104,484			77,866
Intersegment		(104	)		(125	)		(306	)
Consolidated net sales	$	563,003		$	499,023		$	452,246

Operating Income
Biotechnology	$	175,163		$	168,613		$	165,226
Protein Platforms		9,648			3,592			4,469
Diagnostics		28,575			30,412			23,981
Segment operating income		213,386			202,617			193,676
Costs recognized upon sale of acquired inventory		(3,037	)		(5,431	)		(6,952	)
Amortization of intangibles		(44,393	)		(29,395	)		(26,169	)
Stock based compensation		(14,631	)		(9,430	)		(5,957	)
Acquisition related expenses		(25,789	)		(2,761	)		(4,519	)
Corporate general, selling and administrative expenses		(4,952	)		(5,007	)		(3,056	)
Consolidated operating income	$	120,584		$	150,593		$	147,023

	Year Ended June 30,
	2017		2016		2015
External sales
United States	$	313,195	$	275,859	$	245,217
EMEA, excluding U.K.		125,126		103,060		104,178
U.K.		28,401		28,307		32,309
APAC, excluding Greater China		41,463		38,137		24,015
Greater China		39,078		36,199		34,933
Rest of world		15,740		17,461		11,594
Total external sales	$	563,003	$	499,023	$	452,246

Long-lived assets
United States and Canada	$	119,859	$	116,830	$	117,224
Europe		14,100		14,423		11,239
China		1,165		1,109		1,286
Total long-lived assets	$	135,124	$	132,362	$	129,749